CD8A and neoplasm: In the field of oncology, a recent study explored the potential of rhesus cytomegalovirus (RhCMV) vectors, genetically engineered to trigger an HLA-E-restricted CD8+ T cell response targeting tumor-associated antigens (TAAs), in generating an effective anti-tumor reaction against prostate cancer (69).